🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cationic amino acid transport and viral binding of MmCAT1 Fantastic work by Mingda Ye and colleagues at Centre for Medicines Discovery, STRUBIOxford, CAMS Oxford Institute, and the im2pact researchsquare.com/article/rs-467…

Our latest manuscript on a new cell cycle dependent control of dna repair. Started from a high resolution crispr screen of #ubiquitin system after IR: check table S2! Also substrates of cyclin f through motif search! science.org/doi/10.1126/sc…

Novel DDR #ubiquitin MOA based on CRISPR & Proteomics Discovery Oxford Discovery Proteomics

We are hiring! Two structural biology/biochemistry postdoc positions are available in our lab - come and join a lively Team in the thriving city of Oxford! Deadline 4th October 2024. Further details are here: my.corehr.com/pls/uoxrecruit…

We're hiring! I'm looking for a highly-motivated postdoc with experience in biochemistry, #proteomics, and #HDX-MS to join my lab Centre for Medicines Discovery University of Oxford. Please share and/or click on the link for more details! tinyurl.com/mshnw9j9

Adán Pinto Fernández has been awarded a prestigious 2-year grant from Boehringer Ingelheim. Find out more here: camsoxford.ox.ac.uk/news/adan-pint…

Our new paper demonstrating reversible ubiquitylation of DNA and RNA: embopress.org/doi/full/10.10…

Ivan Ahel Lab Expanding the Ubiquitin Code: E3s/DUBs control nucleic acid ubiquitylation - nice collaboration with the Ivan Ahel Lab

Preprint alert 🚨 . Another great collaboration with Aysegul Sapmaz and Paul Geurink in Leiden. This time we identified and characterised USP24 as a deISGylating enzyme with roles in IFN-I production and potential use as an antiviral target. #ubiquitomics

Nucleophagy molecular details revealed by Oxford Discovery Proteomics - great collaboration with Kristijan Ramadan Laboratory Vincenzo DAngiolella OxfordOncology @CMD

A team of international researchers at Oxford University and NTU Singapore have discovered a new process for repairing damaged DNA that is particularly relevant for patients undergoing colorectal cancer treatments. More info ⬇️ ox.ac.uk/news/2024-09-1…

Interested in Ubiquitin, Parkinson’s disease therapy, mitochondria or DUB inhibitors? This preprint may be for you: We show how the deubiquitinase USP30 can specifically be inhibited & introduce a framework for DUB ligandability. biorxiv.org/content/10.110… Thread👇 – with movie!!

BPGbio and NDM’s Centre for Medicines Discovery have announced a research collaboration focused on advancing novel #ProteinDegradation technologies with the goal of unlocking new therapeutic pathways for conditions with limited treatment options. Find out more 👉 ndm.ox.ac.uk/news/cmd-colla…

Looking for E3 / PROTAC / glue or DUB / DUBTAC substrates? Proxy-Ubiquitomics might be the way - applied here to USP30 Andreas Damianou Hannah Jones Oxford Discovery Proteomics biorxiv.org/cgi/content/sh… #biorxiv_molbio

Want to profile your favourite protein's molecular environment? Here a detailed APEX2-based protocol applied to spatially resolve the NLRP3 inflammasome zhu liang Andreas Damianou Frederik Heymann Lassen Oxford Discovery Proteomics CAMS Oxford Institute Centre for Medicines Discovery sciencedirect.com/science/articl…

NEW: Oxford has officially signed a strategic alliance with EIT Oxford to address humanity's greatest challenges. The alliance is centred on collaboration to accelerate innovation across EIT's four Humane Endeavours: - Health and medical science - Food security and sustainable

📢Ubiquigent launches DUBprofiler Open Access Initiative Many #DUB inhibitors in the public domain have inadequately characterised selectivity. To counter this, we're inviting scientists to submit non-proprietary compounds for characterisation at no cost: bit.ly/4f8GDOP

Protein waste turned into antibiotics as a defence strategy of human cells nature.com/articles/d4158…

👏 Success in our Building 👏 We are happy to share that Kessler Group Oxford Andreas Damianou zhu liang James Henderson have received the John Fell OUP Research Fund 🏆 to explore the role of the ubiquitin system in neuroinflammation and microglia biology 🔬🧫. #Congratulations

obABPP-HT*: A Precision-Engineered Activity Proteomics Pipeline for the Streamlined Discovery of Deubiquitinase Inhibitors biorxiv.org/content/10.110… #biorxiv_biochem